PRO_SELECT: Combining structure-based drug design and array-based chemistry for rapid lead discovery. 2. The development of a series of highly potent and selective factor Xa inhibitors

Journal of Medicinal Chemistry

Volumn 45, Issue 6, 2002, Pages 1221-1232

  Liebeschuetz, John W ^a   Jones, Stuart D ^a   Morgan, Phillip J ^a   Murray, Chris W ^a   Rimmer, Andrew D ^a   Roscoe, Jonathan M E ^a   Waszkowycz, Bohdan ^a   Welsh, Pauline M ^a   Wylie, William A ^a   Young, Stephen C ^a   Martin, Harry ^a   Mahler, Jacqui ^a   Brady, Leo ^b   Wilkinson, Kay ^b  

^a BIOCOMPATIBLES UK LTD   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; [N [4 [(1 ACETIMIDOYL 4 PIPERIDYL)OXY]PHENYL] N [(7 AMIDINO 2 NAPHTHYL)METHYL]SULFAMOYL]ACETIC ACID METHANESULFONATE; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; SERINE PROTEINASE;

ARTICLE; CHEMISTRY; COMBINATORIAL LIBRARY; COMPUTER MODEL; DRUG DESIGN; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; SCREENING;

ANIMALS; BENZAMIDINES; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG DESIGN; ENZYME INHIBITORS; FACTOR XA; HUMANS; MODELS, MOLECULAR; PROTEIN CONFORMATION; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037075838     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm010944e     Document Type: Article

References (39)

1. Small-molecule direct thrombin inhibitors
2. Progress towards the discovery of orally active thrombin inhibitors
3. Strategies and progress towards the ideal orally active thrombin inhibitor
4. Recent advances in inhibitors of factor Xa in the prothrombinase complex
5. Factor Xa inhibitors: Today and beyond
6. Factor Xa inhibitors
7. The therapeutic potential of novel anticoagulants
8. Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa: Comparison of a direct thrombin inhibitor and antithrombin III-dependent anticoagulants
9. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris
10. The de novo design and synthesis of cyclic urea inhibitors of Factor Xa: Initial SAR studies
11. Identification and initial structure-activity relationships of a novel class of nonpeptide inhibitors of blood coagulation
12. Design and synthesis of potent and selective 5,6-fused heterocyclic thrombin inhibitors
13. Structure of human des(1-45) factor Xa at 2.2 Å resolution
14. DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa
15. Protective effects of DX-9065a, an orally active novel synthesized and selective inhibitor of factor Xa, against thromboplastin-induced experimental disseminated intravascular coagulation in rats
16. Comparison of the anticoagulant and antithrombotic effects of YM-75466, a novel orally-active factor Xa inhibitor and warfarin in mice
17. X-ray structure of active site-inhibited clotting factor Xa
18. PRO_SELECT: Combining structure-based drug design and combinatorial chemistry for rapid lead discovery. 1. Technology
19. The use of composite crystal-field environments in molecular recognition and the de novo design of protein ligands
20. Receptor surface models. 1. Definition and construction
21. Flexible docking using tabu search and an empirical estimate of binding affinity
22. The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure
23. Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes
24. Empirical Scoring Functions. II. The testing of an empirical scoring function for the prediction of ligand-receptor binding affinities and the use of Bayesian Regression to improve the quality of the model
25. Targeted molecular diversity in drug discovery - Integration of structure-based design and combinatorial chemistry
26. Structure-based design and combinatorial chemistry yield low nanomolar inhibitors of cathepsin D
27. Combinatorial docking and combinatorial chemistry: Design of potent non-peptide thrombin inhibitors
28. Unexpected binding mode of tick anticoagulant peptide complexed to bovine factor Xa
29. In vitro and in vivo characterization of a neutral boron-containing thrombin inhibitor
30. Crystal structure of bovine b-trypsin at 1.5 Å resolution in a crystal form with low molecular packing density
31. Processing of X-ray diffraction data collected in oscillation mode
32. The CCP4 suite: Programs for protein crystallography
33. Improved methods for building protein structures in electron-density maps and the location of errors in these models